Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
scientific article
Author/s
author: Elisabetta Abruzzese, Oliver Ottmann, Giuseppe Saglio, Andreas Hochhaus, Richard A. Larson, Hagop Kantarjian, Jorge Eduardo Cortes, Giovanni Martinelli, Michele Baccarani, Francis Giles, Norbert Gattermann, Kazimierz Kuliczkowski, Jane F Apperley, Jerald P Radich, Philipp le Coutre, Francois-Xavier Mahon, Yaping Shou
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.